All lobbying filings
TODD STRATEGY GROUP
Lobbying for PMI US CORPORATE SERVICES INC. · Tobacco manufacturing company.
Filing
3rd Quarter - Report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbyists on this filing
6
-
DANIEL M TODDPreviously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
-
ERIC BERGRENPreviously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
-
KATHERINE FLEMING COTTONPreviously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
-
PAUL EDATTELPreviously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
-
TED LEHMANPreviously held: Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant
-
JEFF LUCASPreviously held: Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon
Government bodies contacted
2
Lobbying activity
3
Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to tobacco harm reduction. Discussions related to enforcement of illicit tobacco products, including importation of counterfeit products. Discussions related to user fees for tobacco and electronic nicotine delivery system products. Discussions related to efforts to prevent youth access to tobacco products.
Discussions concerning the FY 2024 appropriations bills; provisions related to FDA regulation of tobacco.
Discussions concerning federal funding related to the Centers for Disease Control and Prevention.